SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-19-074693
Filing Date
2019-12-20
Accepted
2019-12-20 09:07:05
Documents
5
Period of Report
2019-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm1926567-4_8k.htm 8-K 25850
2 EXHIBIT 4.1 tm1926567d4_ex4-1.htm EX-4.1 104546
3 EXHIBIT 10.1 tm1926567d4_ex10-1.htm EX-10.1 207653
4 EXHIBIT 99.1 tm1926567d4_ex99-1.htm EX-99.1 8883
5 GRAPHIC tm1926567d4_ex99-1img01.jpg GRAPHIC 4766
  Complete submission text file 0001104659-19-074693.txt   354914
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 191297804
SIC: 2834 Pharmaceutical Preparations